This study is looking at how giving premature infants a supplement called Enfamil® DHA & ARA affects their bodies. Specifically, researchers want to understand how this supplement impacts their lipid (fat) metabolism, inflammation, and organ development. You might be able to join if your baby was born very prematurely (between 25 weeks and 29 weeks and 6 days of pregnancy) and is less than 48 hours old. The study will measure levels of fatty acids in your baby's blood and red blood cells, and a marker for inflammation (Lipoxin A4), from when they start the supplement until they reach 36 weeks post-menstrual age. The current recruitment status is unclear.

Study design

This interventional study plans to enroll 328 premature infants. Infants will be randomly assigned to one of four groups to receive the Enfamil® DHA & ARA supplement, and there is no blinding or placebo group.

What's involved

Infants will receive the Enfamil® DHA & ARA supplement through an enteral tube or oral syringe from within 48 hours after birth until 36 weeks post-menstrual age. If you are breastfeeding, you will be asked to provide milk samples, and your medical history and demographic information will be recorded.

Compensation

Not stated in the trial record.

Follow-up

Your baby's fatty acid levels and a biomarker will be measured from the start of the study until they reach 36 weeks post-menstrual age.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.